IFPMA announces Amgen as new member company

Published on: 10 November 2010

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Amgen has become its newest member company.

IFPMA Director General Eduardo Pisani said: “Amgen is a major force in the increasingly significant biotech sector and is therefore an important and welcome addition to the IFPMA. Amgen will provide us with new perspectives on emerging issues and, I hope, the IFPMA’s experience in dealing with global issues will be able to help Amgen as it expands its geographical presence.”

A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. Amgen’s headquarters are in Thousand Oaks, California, USA. For general information on Amgen, please go to www.amgen.com.

For details of the company’s corporate citizenship activities, please go to www.amgen.com/citizenship/overview.html.

Washington DC, 10 November 2010


IFPMA represents research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry's 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.


Abigail Jones